Conclusion
We describe a case of a patient receiving bamlanivimab infusion for
COVID-19. Based on the uncertainty of causality in this case, it may be
worthwhile to monitor older adults who receive bamlanivimab for longer
than the recommended 60 minutes after administration. Further study of
potential side effects of novel therapeutic agents against COVID-19,
specifically pertaining to the geriatric population, is advised.